'''Tofenacin''' is an [[antidepressant]] [[drug]] with a [[tricyclic]]-like [[chemical structure|structure]] which was developed and marketed in the [[United Kingdom]] and [[Italy]] in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of [[Astellas Pharma]]).<ref name="Index Nominum 2000: International Drug Directory">{{cite book | title = Index Nominum 2000: International Drug Directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1041 | accessdate = 19 May 2012 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | page = 1041}}</ref><ref name="Buckingham1996">{{cite book | author = J. Buckingham | title = Dictionary of organic compounds: Chemical Abstracts Service registry number index | url = https://books.google.com/books?id=2Ggj1SncMBEC&pg=PA6074 | accessdate = 19 May 2012 | year = 1996 | publisher = CRC Press | isbn = 978-0-412-54090-5 | page = 6074}}</ref><ref name="Pharmaceutical Manufacturing Encyclopedia, 3rd Edition">{{cite book | title = Pharmaceutical Manufacturing Encyclopedia, 3rd Edition | url = https://books.google.com/books?id=TIu28TH_iAYC&pg=PA3268 | accessdate = 19 May 2012 | publisher = Elsevier | isbn = 978-0-8155-1526-5 | page = 3268}}</ref> It acts as a [[serotonin-norepinephrine reuptake inhibitor]],<ref name="EllisWest1978">{{cite book | author1 = Gwynn Pennant Ellis | author2 = Geoffrey Buckle West | title = Progress in Medicinal Chemistry | url = https://books.google.com/books?id=YN9YWk4T4fwC&pg=PA284 | accessdate = 19 May 2012 | date = 1 January 1978 | publisher = Elsevier | isbn = 978-0-7204-0655-9 | page = 284}}</ref> and based on its close relation to [[orphenadrine]], may also possess [[anticholinergic]] and [[antihistamine]] properties.  Tofenacin is also the major [[active metabolite]] of orphenadrine and likely plays a role in its beneficial effects against [[major depression|depressive]] [[symptom]]s seen in [[Parkinson's disease]] patients.<ref name="pmid800383">{{cite journal |vauthors=Capstick N, Pudney H | title = A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy | journal = The Journal of International Medical Research | volume = 4 | issue = 6 | pages = 435–40 | year = 1976 | pmid = 800383 | doi = | url = }}</ref><ref name="pmid2616635">{{cite journal |vauthors=Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V | title = Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine | journal = Pharmacopsychiatry | volume = 22 | issue = 6 | pages = 246–9 |date=November 1989 | pmid = 2616635 | doi = 10.1055/s-2007-1014608| url = }}</ref>
